8-K: Breeze Holdings Shareholders Approve YD Biopharma Merger

Breeze Holdings Acquisition Corp. stockholders have approved the business combination with YD Biopharma Limited, paving the way for the combined entity, YD Bio Limited, to trade on Nasdaq under the ticker YDES.

Summary

• A Special Meeting of Stockholders of Breeze Holdings Acquisition Corp. was held on August 14, 2025, where 3,128,495 shares, representing 93.0% of the 3,364,413 outstanding shares, were voted.
• All proposals presented at the Special Meeting were approved by the Company's stockholders.
• The Business Combination Proposal with YD Biopharma Limited was approved with 3,127,474 votes for, 1,000 against, and 21 withheld.
• The Charter Proposal and all Advisory Charter Proposals, including changes to authorized share capital, amendment requirements, removal of blank check provisions, and board classification, were also approved.
• The Pubco Incentive Plan and the Redemption Limitation Amendment Proposal were approved.
• In connection with the meeting, 49,715 shares of common stock were redeemed, leaving 3,314,698 shares outstanding.
• The combined company will operate as YD Bio Limited and is expected to begin trading on the Nasdaq Stock Market under the ticker symbol YDES.
• The closing of the business combination is expected to occur within the next two weeks, subject to customary closing conditions.

Sentiment

Score: 8

Explanation: The overwhelming approval of all proposals by stockholders, including the core business combination and related governance changes, indicates strong support for the merger. The imminent closing and planned Nasdaq listing are positive developments for the combined entity.

Positives

• All proposals, including the critical Business Combination Proposal, received overwhelming stockholder approval, indicating strong support for the merger.
• The transaction is expected to close imminently, within the next two weeks, providing clarity and certainty for investors.
• The combined company, YD Bio Limited, is anticipated to list and trade on the Nasdaq Stock Market under the new ticker symbol YDES, enhancing liquidity and visibility.
• The approval of the Pubco Incentive Plan provides a framework for attracting and retaining talent for the combined entity.
• The elimination of the $5,000,001 net tangible assets redemption limitation provides greater flexibility for future redemptions.

Risks

• Forward-looking statements are subject to significant business, economic, and competitive risks, uncertainties, and other factors that may cause actual results and timing of future events to differ materially.
• Actual results may differ from anticipated outcomes due to factors beyond the company's control.
• Forecasts and estimates regarding YD Biopharma's industry and end markets are based on sources believed to be reliable, but there is no assurance these will prove accurate.
• Projected financial information and other estimates are based on assumptions inherently subject to various significant risks and uncertainties.

Future Outlook

The combined company will operate as YD Bio Limited, with its ordinary shares expected to begin trading on the Nasdaq Stock Market under the ticker symbol YDES. The closing of the business combination is anticipated within the next two weeks. YD Biopharma Limited is a clinical-stage biopharmaceutical company focused on cancer prevention medical diagnostics and the development of exosome-based therapeutics, with ongoing efforts in supplying clinical trial drugs and post-market auxiliary products.

Management Comments

• The press release, signed by J. Douglas Ramsey, Chief Executive Officer and Chief Financial Officer of Breeze Holdings Acquisition Corp., announced that stockholders voted to approve the previously announced business combination with YD Biopharma Limited.

Industry Context

This announcement marks the successful completion of a SPAC business combination, bringing a clinical-stage biopharmaceutical company, YD Biopharma, to the public markets. YD Biopharma's focus on innovative vaccines, therapeutic biologics for infectious diseases, cancer prevention diagnostics, and exosome-based therapeutics aligns with key growth areas in the biopharmaceutical industry, addressing high unmet medical needs and leveraging advanced biotechnologies.

Corporate Governance

Stakeholder Impact

• Shareholders of Breeze Holdings: Their investment will transition from a SPAC to a publicly traded biopharmaceutical company, YD Bio Limited, with shares expected to trade on Nasdaq.
• YD Biopharma: Gains access to public capital markets and increased visibility as a Nasdaq-listed entity.
• Employees of the combined entity: Benefit from the approval of the Pubco Incentive Plan, which provides for equity-based compensation.

Next Steps

• The closing of the business combination between Breeze Holdings Acquisition Corp. and YD Biopharma Limited is expected to occur within the next two weeks.
• Upon closing, the combined company will operate as YD Bio Limited.
• The ordinary shares of YD Bio Limited are expected to begin trading on the Nasdaq Stock Market under the new ticker symbol YDES.

Key Dates

Recommendation

The business combination has been approved by an overwhelming majority of shareholders, and the transaction is expected to close imminently, with the combined entity listing on Nasdaq. This removes significant uncertainty associated with the SPAC process. However, the filing does not provide detailed financial performance or outlook for YD Biopharma itself, which is crucial for a 'buy' or 'sell' recommendation. Investors should hold and await further financial disclosures from the newly combined YD Bio Limited to assess its fundamental value and growth prospects in the biopharmaceutical sector.

Keywords

SPAC, Biopharma, Merger, Acquisition, YD Biopharma, Breeze Holdings, Nasdaq, YDES, Biotechnology, Healthcare, Special Purpose Acquisition Company, SEC Filing, Stockholder Vote